Arrowhead Research | ARWR - Ebit


Arrowhead Research reported $40.81M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Novartis USD -9.19B 13.87B Jun/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -47.52M 24.69M Sep/2025